Bionano genomics announces publication of the first study to combine ogm and ngs to evaluate myeloid cancers

San diego, jan. 26, 2022 (globe newswire) -- bionano genomics, inc. (bngo), pioneer of optical genome mapping (ogm) solutions on the saphyr® system and provider of nxclinical™, the leading software solutions for visualization, interpretation and reporting of genomic data today announced the publication of a study that evaluated the performance and clinical utility of combining ogm and a 523-gene next-generation sequencing (ngs) panel for comprehensive evaluation of myeloid tumors and compared it to standard cytogenetic methods (karyotyping and fluorescence in situ hybridization (fish) and a 54-gene ngs panel.
BNGO Ratings Summary
BNGO Quant Ranking